Literature DB >> 17190912

Effects of acute and chronic L-arginine treatment in experimental hyperuricemia.

Laura G Sánchez-Lozada1, Edilia Tapia, Rubén López-Molina, Tomás Nepomuceno, Virgilia Soto, Carmen Avila-Casado, Takahiko Nakagawa, Richard J Johnson, Jaime Herrera-Acosta, Martha Franco.   

Abstract

Experimental hyperuricemia (HU) results in preglomerular arteriolopathy, cortical vasoconstriction, and glomerular hypertension. Recently, uric acid has been shown to induce endothelial dysfunction. We therefore studied the effect of acute and chronic administration of l-arginine (a substrate for endothelial nitric oxide synthase) on the renal hemodynamic and vascular structural alterations induced by HU. To induce HU, oxonic acid (OA; 750 mg.kg(-1).day(-1)) was administered in male Sprague-Dawley rats. To study the acute effect of arginine, nine rats received l-arginine (l-Arg; 15 mg.kg(-1).min(-1)) during micropuncture. To elucidate the chronic effect of l-Arg, OA + 1% l-Arg (n = 8) and OA + 2.5% l-Arg (n = 6; drinking water) were evaluated throughout the 5-wk period. Eight normal control (N), and eight OA, rats were also studied. Kidneys were fixed by perfusion and afferent arteriole morphology was evaluated. HU rats developed the renal functional and structural alterations described and had suppressed urinary excretion of NO(2)(-)/NO(3)(-). Acute stimulation of nitric oxide (NO) synthesis markedly increased urinary NO(2)(-)/NO(3)(-), lowered systemic blood pressure, and relieved cortical vasoconstriction despite a significant increment of glomerular hypertension and afferent arteriole damage. Increasing doses of chronic l-Arg were associated with increasing excretion of urinary NO(2)(-)/NO(3)(-), reduction of systemic hypertension, and prevention of cortical vasoconstriction (2.5% l-Arg). In addition, both doses prevented glomerular hypertension and preglomerular arteriolopathy. Thus an acute relief of renal vasoconstriction in the setting of afferent arteriole damage cannot reverse glomerular hypertension, likely due to impairment in preglomerular autoregulation. On the other hand, chronic l-Arg preserved arteriolar structures probably mediated by the antiproliferative effect of NO on vascular smooth muscle cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17190912     DOI: 10.1152/ajprenal.00164.2006

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  57 in total

Review 1.  Uric acid as a mediator of diabetic nephropathy.

Authors:  Diana I Jalal; David M Maahs; Peter Hovind; Takahiko Nakagawa
Journal:  Semin Nephrol       Date:  2011-09       Impact factor: 5.299

2.  Uric acid levels are associated with endothelial dysfunction and severity of coronary atherosclerosis during a first episode of acute coronary syndrome.

Authors:  Mélanie Gaubert; Marion Marlinge; Marine Alessandrini; Marc Laine; Laurent Bonello; Julien Fromonot; Jennifer Cautela; Franck Thuny; Jeremie Barraud; Giovanna Mottola; Pascal Rossi; Emmanuel Fenouillet; Jean Ruf; Régis Guieu; Franck Paganelli
Journal:  Purinergic Signal       Date:  2018-04-06       Impact factor: 3.765

3.  Relevance of uric acid and asymmetric dimethylarginine for modeling cardiovascular risk prediction in chronic kidney disease patients.

Authors:  Mehmet Kanbay; Baris Afsar; Dimitrie Siriopol; Hilmi Umut Unal; Murat Karaman; Mutlu Saglam; Tayfun Eyileten; Mustafa Gezer; Samet Verim; Yusuf Oguz; Abdulgaffar Vural; Alberto Ortiz; Richard J Johnson; Adrian Covic; Mahmut Ilker Yilmaz
Journal:  Int Urol Nephrol       Date:  2016-03-23       Impact factor: 2.370

4.  EGF Receptor Inhibition Alleviates Hyperuricemic Nephropathy.

Authors:  Na Liu; Li Wang; Tao Yang; Chongxiang Xiong; Liuqing Xu; Yingfeng Shi; Wenfang Bao; Y Eugene Chin; Shi-Bin Cheng; Haidong Yan; Andong Qiu; Shougang Zhuang
Journal:  J Am Soc Nephrol       Date:  2015-03-18       Impact factor: 10.121

Review 5.  Uric acid as a target of therapy in CKD.

Authors:  Diana I Jalal; Michel Chonchol; Wei Chen; Giovanni Targher
Journal:  Am J Kidney Dis       Date:  2012-10-09       Impact factor: 8.860

6.  Uric acid level and erectile dysfunction in patients with coronary artery disease.

Authors:  Yalcin Solak; Hakan Akilli; Mehmet Kayrak; Alpay Aribas; Abduzhappar Gaipov; Suleyman Turk; Santos E Perez-Pozo; Adrian Covic; Kim McFann; Richard J Johnson; Mehmet Kanbay
Journal:  J Sex Med       Date:  2013-09-25       Impact factor: 3.802

7.  Vascular Function and Uric Acid-Lowering in Stage 3 CKD.

Authors:  Diana I Jalal; Emily Decker; Loni Perrenoud; Kristen L Nowak; Nina Bispham; Tapan Mehta; Gerard Smits; Zhiying You; Douglas Seals; Michel Chonchol; Richard J Johnson
Journal:  J Am Soc Nephrol       Date:  2016-09-12       Impact factor: 10.121

Review 8.  Redox control of renal function and hypertension.

Authors:  Ravi Nistala; Adam Whaley-Connell; James R Sowers
Journal:  Antioxid Redox Signal       Date:  2008-12       Impact factor: 8.401

9.  Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia.

Authors:  Laura G Sánchez-Lozada; Virgilia Soto; Edilia Tapia; Carmen Avila-Casado; Yuri Y Sautin; Takahiko Nakagawa; Martha Franco; Bernardo Rodríguez-Iturbe; Richard J Johnson
Journal:  Am J Physiol Renal Physiol       Date:  2008-08-13

Review 10.  The Impacts of Serum Uric Acid on arterial hemodynamics and Cardiovascular Risks.

Authors:  Pai-Feng Hsu; Shao-Yuan Chuang; Wen-Chung Yu; Hsin-Bang Leu; Wan-Leong Chan; Chen-Huan Chen
Journal:  Acta Cardiol Sin       Date:  2013-03       Impact factor: 2.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.